Using Botox to Reduce Dry Mouth in Prostate Cancer Patients Undergoing Radiopharmaceutical Therapy
A new study shows that Botox injections combined with anti-nausea patches can significantly reduce salivary gland toxicity, improving quality of life for prostate cancer patients receiving radiopharmaceutical therapy.
Prostate cancer patients treated with radiopharmaceutical therapy, especially with alpha-emitting agents like Actinium-225 (225Ac-PSMA), often face the challenging side effect of severe dry mouth caused by salivary gland toxicity. Traditional methods such as cold packs, anticholinergic drugs, or external cooling have provided limited relief. However, recent research introduces a promising dual-protection strategy involving botulinum toxin (Botox) injections and anti-nausea patches.
In a study presented at the Society of Nuclear Medicine and Molecular Imaging 2025 Annual Meeting, 14 patients received Botox injections into their parotid and submandibular salivary glands three to four weeks before undergoing combined Actinium-225 and Lutetium-177 PSMA radiotherapy. Alongside, patients wore nausea patches behind the ears starting three days prior to treatment, continuing until two hours afterward. Molecular imaging scans before and after therapy revealed a significant reduction in the glands' radioligand uptake.
The results showed an average 30% decrease in PSMA uptake in the treated parotid glands and an 17% reduction in the submandibular glands. The procedure was well tolerated, with only mild discomfort reported, and no participants had to discontinue therapy due to dry mouth. This reduction in salivary gland uptake indicates a lowered risk of damage and dryer mouth symptoms, which can greatly improve patient quality of life.
Dr. Jingjing Zhang, a lead researcher from the National University of Singapore, highlighted that combining Botox with nausea patches is a safe, effective method to protect salivary glands without compromising the therapy's ability to target prostate tumors. Importantly, both Botox and nausea patches are already FDA-approved medications, facilitating easier translation into clinical practice.
This innovative approach might significantly enhance treatment outcomes by reducing salivary gland toxicity, thereby making PSMA-targeted radiotherapy more tolerable. As dry mouth is a common and distressing side effect that impacts patient adherence, this strategy holds promise for improving overall patient well-being during prostate cancer treatment.
Source: https://medicalxpress.com/news/2025-06-botox-mitigates-debilitating-dry-mouth.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Shorter Telomeres and the Risk of Age-Related Brain Diseases
Shorter telomeres are linked to a higher risk of age-related brain diseases, but healthy lifestyle choices may mitigate this risk. New research suggests that behavioral changes can help protect cognitive health as we age.
Distinct Pathways in Macrophages Regulate Inflammation and Lysosomal Function During Toxic Particle Exposure
New research reveals that macrophages activate separate pathways to manage inflammation and lysosomal function during exposure to toxic particles, opening doors for targeted therapies in related diseases.
Understanding How Viruses Exploit Weaknesses in Antibody Defense
Recent research reveals how SARS-CoV-2 develops mutations to evade monoclonal antibody treatments. Combining multiple antibodies could prevent viral escape and improve therapeutic efficacy.
Lasso-LR Model Identified as Best Predictor for AKI Mortality in Alcoholic Cirrhosis Patients
A groundbreaking study reveals that the Lasso-LR machine learning model is highly effective in predicting mortality risks for patients with alcoholic cirrhosis and severe AKI, aiding personalized treatment strategies.